7th Sep 2015 05:21
LONDON (Alliance News) - Starpharma on Monday announced it has signed a licensing agreement with AstraZeneca PLC for development and commercialisation of compounds directed at a defined family of targets using its DEP drug delivery technology.
AstraZeneca will fund all development and commercialisation costs under the agreement, including ongoing and future collaborative work conducted with Starpharma.
Under the agreement, Starpharma will receive a signature payment of USD2 million and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP product of USD124 million.
Starpharma said its other programmes, including its wholly-owned DEP docetaxel product, are not negatively impacted by this arrangement.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca